Cargando…

Long-term outcomes of prostate intensity-modulated radiation therapy incorporating a simultaneous intra-prostatic MRI-directed boost

PURPOSE/OBJECTIVES: This retrospective study demonstrates the long-term outcomes of treating prostate cancer using intensity modulated (IMRT) with incorporation of MRI-directed boost. MATERIALS/METHODS: From February 2009 to February 2013, 78 men received image-guided IMRT delivering 77.4 Gy in 44 f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laughlin, Brady S., Silva, Alvin C., Vora, Sujay A., Keole, Sameer R., Wong, William W., Schild, Michael H., Schild, Steven E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399820/ https://www.ncbi.nlm.nih.gov/pubmed/36033460 http://dx.doi.org/10.3389/fonc.2022.921465

Ejemplares similares

Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy
por: Liu, Xiaonan, et al.
Publicado: (2017)

Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: Early experience
por: Laughlin, Brady S., et al.
Publicado: (2022)

Clinical Practice Evolvement for Post-Operative Prostate Cancer Radiotherapy—Part 2: Feasibility of Margin Reduction for Fractionated Radiation Treatment with Advanced Image Guidance
por: Laughlin, Brady S., et al.
Publicado: (2022)

Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ≥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers
por: Liu, Xiaonan, et al.
Publicado: (2016)

Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy
por: Laughlin, Brady S., et al.
Publicado: (2022)

Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity
por: Choo, Richard, et al.
Publicado: (2021)

Modeling of Acute Rectal Toxicity to Compare Two Patient Positioning Methods for Prostate Cancer Radiotherapy: Can Toxicity Modeling be Used for Quality Assurance?
por: Liu, X, et al.
Publicado: (2018)

Development of a treatment planning protocol for prostate treatments using intensity modulated radiotherapy
por: Ezzell, Gary A., et al.
Publicado: (2001)

Clinical Practice Evolvement for Post-Operative Prostate Cancer Radiotherapy—Part 1: Consistent Organs at Risk Management with Advanced Image Guidance
por: Laughlin, Brady S., et al.
Publicado: (2022)

Monte Carlo dose verification of prostate patients treated with simultaneous integrated boost intensity modulated radiation therapy
por: Dogan, Nesrin, et al.
Publicado: (2009)

Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers
por: Osman, Sarah O. S., et al.
Publicado: (2022)

Advantages of intensity modulated proton therapy during hippocampal avoidance whole brain radiation therapy
por: Stoker, Joshua, et al.
Publicado: (2018)

Toxicity of Tomotherapy-Based Simultaneous Integrated Boost in Whole-Pelvis Radiation for Prostate Cancer
por: You, Sei Hwan, et al.
Publicado: (2015)

Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control
por: Saracino, Biancamaria, et al.
Publicado: (2014)

Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy
por: Bulman, Gabriella F., et al.
Publicado: (2021)

Biologically Effective Dose and Rectal Bleeding in Definitive Proton Therapy for Prostate Cancer
por: Bhangoo, Ronik S., et al.
Publicado: (2021)

Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study
por: Onishi, Masahiro, et al.
Publicado: (2021)

Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study
por: Singh, Anurag K, et al.
Publicado: (2007)

Beam mask and sliding window-facilitated deep learning-based accurate and efficient dose prediction for pencil beam scanning proton therapy
por: Zhang, Lian, et al.
Publicado: (2023)

Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation
por: Cante, Domenico, et al.
Publicado: (2020)

A RapidArc planning strategy for prostate with simultaneous integrated boost
por: Jolly, David, et al.
Publicado: (2010)

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003
por: Laughlin, Brady S., et al.
Publicado: (2022)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
por: Mercado, Catherine, et al.
Publicado: (2016)

Outcomes of Proton Beam Therapy Compared With Intensity-Modulated Radiation Therapy for Uterine Cancer
por: Anderson, Justin D., et al.
Publicado: (2022)

Dosimetric advantages of proton beam therapy compared to intensity-modulated radiation therapy for retroperitoneal chordoma
por: Yu, Nathan Y, et al.
Publicado: (2019)

Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer
por: Ekanger, Christian, et al.
Publicado: (2019)

Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer
por: Ahmad Khalil, Dalia, et al.
Publicado: (2022)

Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
por: Schoots, Ivo G., et al.
Publicado: (2019)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
por: Paydar, Ima, et al.
Publicado: (2017)

Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial
por: Ricco, Anthony, et al.
Publicado: (2020)

Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
por: Tree, Alison, et al.
Publicado: (2013)

Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate - first results of the PLATIN 1 trial
por: Habl, Gregor, et al.
Publicado: (2015)

Feasibility of simultaneous integrated boost with forward intensity-modulated radiation therapy for multiple brain metastases
por: Ni, Lingqin, et al.
Publicado: (2014)

Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer
por: Zhou, Heling, et al.
Publicado: (2017)

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018)

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
por: Ricco, Anthony, et al.
Publicado: (2016)

Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison
por: Wu, Trudy C., et al.
Publicado: (2022)

The Addition of Manganese Porphyrins during Radiation Inhibits Prostate Cancer Growth and Simultaneously Protects Normal Prostate Tissue from Radiation Damage
por: Chatterjee, Arpita, et al.
Publicado: (2018)

ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II
por: Zaorsky, Nicholas G., et al.
Publicado: (2017)

ACR Appropriateness Criteria(®) external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II
por: Zaorsky, Nicholas G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jhk6p1kggaj7geu4j4cpkb5qhi